HBV相关肝细胞癌抑癌基因甲基化异常及机制的研究进展  

Research Progress on the Abnormal Methylation and Mechanism of Tumor Suppressor Genes in HBV-associated Hepatocellular Carcinoma

作　　者：陈映均 刘同刚[1] CHEN Yingjun;LIU Tonggang(Binzhou Medical University Hospital,Binzhou 256603,China;不详)

机构地区：[1]滨州医学院附属医院,山东滨州256603

出　　处：《中国医学创新》2023年第23期168-175,共8页Medical Innovation of China

摘　　要：肝细胞癌(HCC)的死亡率位居世界第三,其早期诊断及晚期治疗手段有限。由于甲胎蛋白(AFP)在肝癌早期临床诊断的敏感度较低,以及人们对该病自身及生活方式认识不足,这种癌症的发病率仍在上升。乙型肝炎病毒(HBV)感染作为我国公认的导致肝脏细胞发生癌变的主要危险因素,其可能会加快基因甲基化的进程,继而导致肝细胞癌的发生。DNA甲基化及其诱导的表观遗传学改变,由于其潜在的可逆性,为寻找HCC的新型生物标志物和治疗提供了新的途径。这些抑癌基因甲基化异常在HBV相关HCC发展中的机制仍未被阐明,进一步了解HBV相关HCC表观遗传学的新分子靶点对HCC的诊断、治疗和预防具有重要意义。本文就DNA甲基化介导HBV相关肝细胞癌中抑癌基因甲基化异常及机制进行综述,为攻克肝癌治疗的难点提供新的思路。Hepatocellular carcinoma(HCC)has the third highest cancer mortality rate in the world,and its early diagnosis and late treatment are limited.The incidence of this cancer is still increasing due to the low sensitivity of alpha-fetoprotein(AFP)in the early clinical diagnosis of liver cancer and the lack of awareness of the disease itself and lifestyle.Hepatitis B virus(HBV)infection,as a recognized major risk factor for the occurrence of hepatocellular carcinoma in China,may accelerate the process of gene methylation,which in turn leads to the occurrence of hepatocellular carcinoma.DNA methylation and its induced epigenetic epigenetics changes,due to their potential reversibility,provide a new way to find novel biomarkers and treatments for HCC.The mechanism of aberrant methylation of these tumor suppressor genes in the development of HBV-associated HCC has still not been elucidated.Further understanding of the new molecular targets of HBV-associated HCC epigenetics is of great significance for the diagnosis,prevention,and treatment of HCC.This article reviews the abnormal methylation of tumor suppressor genes mediated by DNA methylation in HBV-associated HCC and its mechanism,so as to provide new ideas for overcoming the difficulties in the treatment of liver cancer.

关 键 词：肝细胞癌 乙型肝炎病毒 抑癌基因 DNA甲基化 

分 类 号：R735.7[医药卫生—肿瘤]